Tags

Type your tag names separated by a space and hit enter

[Tinea capitis. Therapeutic options in the post-griseofulvin era].
Hautarzt. 2002 Dec; 53(12):788-94.H

Abstract

Tinea capitis is the most common dermatophyte infection during childhood. In Germany, only griseofulvin is approved for therapy by regulatory agencies. In recent years, several newer antifungal agents such as itraconazole, fluconazole and terbinafine have broadened the therapeutic armamentarium and are used for the treatment of childhood tinea capitis. Itraconazole and terbinafine seem to be equally or more effective in treatment of tinea capitis within a shorter period of time than griseofulvin. Fluconazole is probably also effective for this indication, although supporting data is limited. Encountered side effects as well as interactions with other drugs appear to be well within acceptable limits for all three drugs. In conclusion, systemic therapy of scalp ringworm with itraconazole and terbinafine, as well as perhaps fluconazole, seems to be an equivalent or a superior therapeutic approach as compared to the use of griseofulvin. For the future, regulatory approval for the use of these newer antifungal agents in tinea capitis of childhood is recommended.

Authors+Show Affiliations

Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, Technische Universität München, Germany. m.moehrenschlager@lrz.tum.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Review

Language

ger

PubMed ID

12444518

Citation

Möhrenschlager, M, et al. "[Tinea Capitis. Therapeutic Options in the Post-griseofulvin Era]." Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete, vol. 53, no. 12, 2002, pp. 788-94.
Möhrenschlager M, Korting HC, Seidl HP, et al. [Tinea capitis. Therapeutic options in the post-griseofulvin era]. Hautarzt. 2002;53(12):788-94.
Möhrenschlager, M., Korting, H. C., Seidl, H. P., Ring, J., & Abeck, D. (2002). [Tinea capitis. Therapeutic options in the post-griseofulvin era]. Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete, 53(12), 788-94.
Möhrenschlager M, et al. [Tinea Capitis. Therapeutic Options in the Post-griseofulvin Era]. Hautarzt. 2002;53(12):788-94. PubMed PMID: 12444518.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Tinea capitis. Therapeutic options in the post-griseofulvin era]. AU - Möhrenschlager,M, AU - Korting,H C, AU - Seidl,H P, AU - Ring,J, AU - Abeck,D, PY - 2002/11/22/pubmed PY - 2003/4/23/medline PY - 2002/11/22/entrez SP - 788 EP - 94 JF - Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete JO - Hautarzt VL - 53 IS - 12 N2 - Tinea capitis is the most common dermatophyte infection during childhood. In Germany, only griseofulvin is approved for therapy by regulatory agencies. In recent years, several newer antifungal agents such as itraconazole, fluconazole and terbinafine have broadened the therapeutic armamentarium and are used for the treatment of childhood tinea capitis. Itraconazole and terbinafine seem to be equally or more effective in treatment of tinea capitis within a shorter period of time than griseofulvin. Fluconazole is probably also effective for this indication, although supporting data is limited. Encountered side effects as well as interactions with other drugs appear to be well within acceptable limits for all three drugs. In conclusion, systemic therapy of scalp ringworm with itraconazole and terbinafine, as well as perhaps fluconazole, seems to be an equivalent or a superior therapeutic approach as compared to the use of griseofulvin. For the future, regulatory approval for the use of these newer antifungal agents in tinea capitis of childhood is recommended. SN - 0017-8470 UR - https://www.unboundmedicine.com/medline/citation/12444518/[Tinea_capitis__Therapeutic_options_in_the_post_griseofulvin_era]_ L2 - https://dx.doi.org/10.1007/s00105-002-0365-5 DB - PRIME DP - Unbound Medicine ER -